Followers | 14 |
Posts | 1,650 |
Boards Moderated | 0 |
Alias Born | 11/01/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If that were the case maybe they would put out the pending news? Especially since we now know we can't get that DTC Chill lifted until they can show revenue
I was wondering if you were still following this
did anyone post the full thing?
Centaurus Diamond Technologies, Inc. CTDT:OTCQB, (the “Company” or “Centaurus”) Issues Shareholder and Business Operations Update
LAS VEGAS, NV / ACCESSWIRE / March 13, 2019 / Centaurus Diamond Technologies, Inc. (the "Company" or "Centaurus") (CTDT:OTCQB)
The Board of Directors and Management wishes to update shareholders on several important matters.
The Company is fully engaged with our DTC sponsoring broker/dealer with respect to the removal of the DTC Chill in order to become DTC Eligible. The Company believes that the delay in achieving the removal of the Chill is related to the "Shell-Risk" status at the OTC. The Compliance Department at the OTC Markets Group attributed our shell-risk designation to our lack of revenue generation on our last audited financials. Centaurus has submitted all of the documentation requested by the DTC to its participating member. Management acknowledges that it has taken longer than anticipated and remains steadfast in our efforts to get the Chill lifted to become DTC Eligible. However, it will not hinder our revenue generating operations from commencing as scheduled.
In addition, we are in the process of relocating our R&D facilities in Pawtucket, Rhode Island to a more suitable and secure location in order to achieve the last milestones necessary before the commercialization of the Magnatech Process. The R&D is an evolutionary process and is expected to be finalized for commercialization by the end of the third quarter of this year.
The Company CEO and President Chas Radovich stated, "We greatly appreciate our shareholders' ongoing support as we get ready to become a revenue generating Company this year. We have begun executing the production and commercialization of our expanding portfolio of products. We are also in discussions for licensing agreements for Industrial and Electronic applications. The Directors and Management of our Company are confident in representing that we will be a sustainable going concern before the end of the year."
About Centaurus Diamond Technologies, Inc.
Centaurus has been established to fully commercialize its proprietary, cost-efficient and high-volume diamond production method to provide industrial quality diamonds. The Company’s patented technology enables the production of "cultured" diamonds that are chemically, atomically and structurally identical to natural diamonds. The Gemological Institute of America has tested the Company's "cultured" diamonds and has confirmed they are diamonds according to their testing protocols.
For more information please contact Chas Radovich at 714-323-1110 or via email at admin@centaurustechnologiesinc.com.
Forward Looking Information
Other than statements of historical fact, this release may contain descriptions of the Company's expectations regarding future business activities. These forward-looking statements are made in reliance upon safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Accordingly, actual results may differ materially from those contemplated by the forward-looking statements.
SOURCE: Centaurus Diamond Technologies, Inc.
View source version on accesswire.com:
https://www.accesswire.com/538863/Centaurus-Diamond-Technologies-Inc-CTDTOTCQB-the-Company-or-Centaurus-Issues-Shareholder-and-Business-Operations-Update
I've been saying this for a looooong time
Nothing has changed here. The company has never moved fast. Fun ride while it lasted. Now back to the waiting game
Scott Gottlieb is out. Good for INNV?
I've been experimenting with CBD vaping lately and it seems like it doesn't do anything but I don't have any of the conditions that it is supposedly good for and I hear edibles are more effective
LT was at least good entertainment
The excitement is gone. Need some action from the company
Considering how we usually trade volume has been pretty good lately
Yeah I know there are a lot of people out there that won't touch a stock under a dollar. Things might get interesting soon.
How do we check to see if the chill is lifted? I tried looking it up but didn't have any luck.
I figure I might as well since we have all waited so long already
Whenever someone is crazy enough to buy this is how it moves
The painter didn't show up for work today?
Well there was only a buy for 800,000 shares this morning so they either came back for more or we got multiple buyers
So who is buying this morning? Lottery tickets
I think most of us longs are holding for the real action
I would think that since its a public list that anyone can sign up for there shouldn't be a problem
My my my
It sure is fun watching my account jump like this. I guess it was worth the LONG wait
The chill going away by Tuesday
Don't try to set your watch to that estimate though
I put a sell order in at $1 yesterday thinking it wouldn't happen anytime soon. It didn't go through though
Holy crap this hit a dollar!!!!
So I wonder what is next
Yeah I posted it a few posts back
Shawn I'm not ready to cry yet. Support me!
Lol I hope we move a lot of Fluiticare
CHICAGO (Legal Newsline) – Pending in Chicago federal court is a drug company's frank response to a doctor who is suing over the marketing of Sensum+.
Innovus Pharmaceuticals Inc. has filed a motion to dismiss a lawsuit filed by James L. Yeager, Ph.D. and Midwest Research Laboratories over allegations of right to publicity and false light regarding the marketing of the product.
Sensum+ is a cream that can be applied to the penis with the goal of an "increase of sensation," the product's website says.
"Plaintiffs’ allegations don’t even make sense. Yeager alleges he suffered 'reputational harm' as a result of the unidentified 'publications,' while at the same time alleging that these publications described his development of the products as miraculous, providing a solution for which men had been begging for years, and providing life changing improvements to men," says the motion, filed in October..
In the 21-page motion, Innovus argues that Yeager “fails to allege facts that establish this court has personal jurisdiction” in this matter.
Innovus also says that Yeager falls short in alleging facts that would be sufficient to warrant action by the court. Finally, Innovus argues that Yeager’s claims of publicity lie outside the statute of limitations under the law, and thus are not applicable.
The plaintiffs filed their original complaint on Jan. 19, 2018. Yeager alleged that Innovus used his identity while marketing Sensum+ without his authorization. This allegedly included using his name and image in advertising for Sesnum+, as well as on the company’s website.
The motion states that the plaintiffs developed CircumSerum and Sensum+ products, sold them and the right to market them to Centric Research Institute, and that the products and the right to market them were sold to Innovus.
Yeager also claims that using his likeness and identity in the advertisements was a violation of his right to publicity under Illinois law. Yet, Innovus argues in its motion that the “the act triggering the statute of limitations occurred more than one year before” Yeager submitted his suit.
Innovus notes that he says he experienced “reputational harm” because his image and identity were in marketing materials. Yet, at the same time, it alleges that he was proud of the products described in the advertising and that they had provided a “solution for which men had been begging for years.”
The company also argues in its motion that Yeager seeks injunctive relief under the Illinois Deceptive Trade Practices Act but failed “to establish any risk of future injury,” and that harm to his reputation is not enough to establish a call for action.
Maybe we can countersue and generate some decent revenue?
https://legalnewsline.com/stories/511724706-lawsuit-over-penis-cream-sensum-doesn-t-even-make-sense-drug-company-says
News or not these never work out for me. I don't have confidence this time will be different.
A goddamn reverse split?! Confirmed?
Damn are oversold or did something just happen?
someone just invested $100, there is hope!
Hopefully
The company paying SeeThruEquity to tell us we going be big is doesn't seem to be helping
I don't think the title fits since I've been holding bags for over two years
Spoke to soon. Closed green but I'm still on the red SMH
WSJ did a podcast on lab grown diamonds today
https://traffic.megaphone.fm/WSJ9012142091.mp3